Session Information
IBMS Davos Workshops: Bone Biology & Therapeutics
Click here to go to the previous page
Interview - R. Scott Pearsall - Acceleron Pharma, Inc., Cambridge, Massachusetts, USA
Track
:
Interview Sessions
Program Code:
10
Description
Abstract 144: Treatment with RAP-011 (a soluble activin receptor type IIA) increases bone mineral density in mice with prior bisphosphonate exposure
Audio Synchronized to PowerPoint
